1. ADRs for selected biologicals and biosimilars comparable

   News item 21 October 2017 Pages: 1 - 1

2. EMA publishes summary from valproate public hearing

   News item 21 October 2017 Pages: 2 - 2

3. EU guidelines updated for better labelling of excipients

   News item 21 October 2017 Pages: 3 - 3

4. Relief System for Adverse Drug Reactions in Japan

   News item 21 October 2017 Pages: 4 - 4

5. New ISoP special interest groups

   News item 21 October 2017 Pages: 5 - 5

6. Pharmacovigilance in Vietnam: NDIADRMC

   Clinical study 21 October 2017 Pages: 6 - 6

7. Branded vs generic extended-release methylphenidate

   Clinical study 21 October 2017 Pages: 7 - 7

8. Dapagliflozin adverse events in phase IIb/III clinical trials

   Clinical study 21 October 2017 Pages: 8 - 8

9. Major bleeding or haematuria with anticoagulants/antithrombotics

   Clinical study 21 October 2017 Pages: 9 - 9

10. Side effect reporting in direct-to-consumer drug advertising

    Clinical study 21 October 2017 Pages: 10 - 10

11. Simvastatin safety: impact of Health Canada warnings

    Clinical study 21 October 2017 Pages: 11 - 11

12. Abacavir/efavirenz/lamivudine

    Case report 21 October 2017 Pages: 12 - 12

13. Ace-inhibitors/omalizumab/perindopril interaction

    Case report 21 October 2017 Pages: 13 - 13

14. Acetazolamide

    Case report 21 October 2017 Pages: 14 - 14

15. Adalimumab/certolizumab pegol

    Case report 21 October 2017 Pages: 15 - 15

16. Adalimumab/infliximab

    Case report 21 October 2017 Pages: 16 - 16

17. Afatinib

    Case report 21 October 2017 Pages: 17 - 17

18. Alcohol/isoprenaline

    Case report 21 October 2017 Pages: 18 - 18

19. Aldesleukin

    Case report 21 October 2017 Pages: 19 - 19

20. Alectinib

    Case report 21 October 2017 Pages: 20 - 20

21. Allopurinol

    Case report 21 October 2017 Pages: 21 - 21

22. Allopurinol

    Case report 21 October 2017 Pages: 22 - 22

23. Alteplase

    Case report 21 October 2017 Pages: 23 - 23

24. Amifampridine

    Case report 21 October 2017 Pages: 24 - 24

25. Amiodarone

    Case report 21 October 2017 Pages: 25 - 25

26. Amiodarone

    Case report 21 October 2017 Pages: 26 - 26

27. Amoxicillin

    Case report 21 October 2017 Pages: 27 - 27

28. Amoxicillin/clarithromycin/vonoprazan

    Case report 21 October 2017 Pages: 28 - 28

29. Amphotericin-B

    Case report 21 October 2017 Pages: 29 - 29

30. Amphotericin-B liposomal

    Case report 21 October 2017 Pages: 30 - 30

31. Amphotericin-B liposomal

    Case report 21 October 2017 Pages: 31 - 31

32. Amphotericin-B-liposomal

    Case report 21 October 2017 Pages: 32 - 32

33. Antidepressants

    Case report 21 October 2017 Pages: 33 - 33

34. Antineoplastics

    Case report 21 October 2017 Pages: 34 - 34

35. Antineoplastics

    Case report 21 October 2017 Pages: 35 - 35

36. Antineoplastics

    Case report 21 October 2017 Pages: 36 - 36

37. Antineoplastics

    Case report 21 October 2017 Pages: 37 - 37

38. Antineoplastics

    Case report 21 October 2017 Pages: 38 - 38

39. Antiretrovirals/metformin/sitagliptin interaction

    Case report 21 October 2017 Pages: 39 - 39

40. Antirheumatics

    Case report 21 October 2017 Pages: 40 - 40

41. Antithymocyte globulin/fludarabine/melphalan

    Case report 21 October 2017 Pages: 41 - 41

42. Antivirals

    Case report 21 October 2017 Pages: 42 - 42

43. Antivirals

    Case report 21 October 2017 Pages: 43 - 43

44. Apremilast

    Case report 21 October 2017 Pages: 44 - 44

45. Asparaginase

    Case report 21 October 2017 Pages: 45 - 45

46. Asparaginase/prednisolone

    Case report 21 October 2017 Pages: 46 - 46

47. Aspirin

    Case report 21 October 2017 Pages: 47 - 47

48. Aspirin

    Case report 21 October 2017 Pages: 48 - 48

49. Aspirin/clopidogrel/enoxaparin sodium

    Case report 21 October 2017 Pages: 49 - 49

50. Aspirin/heparin

    Case report 21 October 2017 Pages: 50 - 50